Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ardelyx, Inc.
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 09, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 01, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
April 26, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
April 18, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
April 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
April 12, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 02, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
February 28, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
February 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.